Financial Performance and Growth - PPL's year-end 2023 rate base was $25.4 billion[10] and market capitalization was $20.4 billion[10] - PPL projects annual EPS and dividend growth of 6% - 8% through at least 2027[11, 43] - PPL targets a total return proposition of 9% - 12%[13, 41] - PPL plans $14.3 billion in capital investments, driving average annual rate base growth of 6.3% through 2027[13] - PPL targets annual O&M savings of at least $175 million by 2026 from a 2021 baseline[13, 65] Regulatory and Operational Efficiency - Approximately 65% of PPL's capital plan is subject to contemporaneous recovery[41, 47] - PPL aims to reduce O&M expenses by an average of 2.5% per year[66] - PPL achieved $75 million in actual 2023 O&M savings[66] - PPL's Pennsylvania segment's 2023 rate base is $9.8 billion, with 44% in electric transmission and 56% in electric distribution[86, 87] - PPL's Rhode Island segment's 2023 rate base is $3.7 billion, with 32% in electric distribution, 27% in gas LDC operations, and 41% in electric transmission[110] - PPL's Kentucky segment's 2023 rate base is $11.9 billion, with 51% in electric generation, 25% in gas LDC operations, 14% in electric distribution, and 10% in electric transmission[139, 140]

Company Overview and Financial Performance - Centrus's market capitalization is $1 billion[19] - The company's 2024 revenue was $442 million[19], with a net income of $73.2 million[19] - The LEU segment accounts for 79% of the 2024 revenue, while the Technical Solutions segment contributes 21%[21] Market Position and Opportunities - Centrus has a significant LEU segment backlog of approximately $2.8 billion, contributing to a total backlog of $3.8 billion extending to 2040[18, 52] - The company estimates a total addressable market (TAM) for HALEU of $6.2 billion per year by 2035[31, 45] - The LEU market opportunity is estimated at $2.4 billion per year for global utilities and $1.9 billion per year for U S reactors[45] HALEU Production and Government Contracts - Centrus has delivered approximately 670 kilograms of HALEU to the Department of Energy as of March 2025[18, 43, 62] - The company won a HALEU Operations Contract with the DOE, potentially worth up to $1.1 billion over 11 years if all options are exercised[64] Impact of Russian Uranium Imports Ban - U S utilities purchased approximately 3.9 million SWU of Russian-origin in 2023, representing 24% of U S demand[38, 39, 68] - The Prohibiting Russian Uranium Imports Act effectively eliminates Russia as a competitor for enriched uranium in the U S post-2027 and released $2.7 billion in funding to promote domestic uranium enrichment[68]

OVERVIEW OF SYSTEM SALES JANUARY 18, 2024 SAFE HARBOR STATEMENT This presentation and oral statements made by management in connection herewith that are not historical facts are "forward ‐ looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward ‐ looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements. They include statements regarding current expectations, estimates, forecas ...

Financial Performance & Outlook - Helios Technologies reported Q1 2024 net sales of $212 million, a decrease of 1% year-over-year[80] - The company anticipates 2024 revenue between $840 million and $860 million[121] - Helios projects 2024 net income to be between $50 million and $63 million[121] - Adjusted EBITDA for 2024 is expected to be in the range of $163 million to $180 million, with an adjusted EBITDA margin between 195% and 210%[121] - The company's net debt to pro forma adjusted EBITDA ratio was 308x at the end of Q1 2024[106] Segment Performance - Hydraulics segment sales in Q1 2024 were $1424 million, a 4% decrease year-over-year[38] - Electronics segment sales in Q1 2024 were $696 million, a 6% increase year-over-year[62] - The company expects Hydraulics revenue between $565 million and $580 million, representing 0% to 2% growth over 2023[111] - The company expects Electronics revenue between $275 million and $280 million, representing 2% to 4% growth over 2023[111] Regional Performance - Americas accounted for 55% of total sales in FY2023[11] - EMEA accounted for 24% of total sales in FY2023[11] - APAC accounted for 21% of total sales in FY2023[11]

Financial Highlights - ChromaDex's total net sales reached $83.5 million in 2023, with Tru Niagen® sales contributing $69.5 million[14] - Tru Niagen® sales experienced a 52% Compound Annual Growth Rate (CAGR)[11] - E-commerce net sales reached $51.2 million in 2023, demonstrating an 85% CAGR[16] - Gross margin increased from 49.4% to 60.8% following a strategic shift towards Tru Niagen®[17] - ChromaDex reported a positive Adjusted EBITDA of $1.9 million in 2023[11, 12] Market and Product - ChromaDex identifies as the global authority on NAD+ with a Total Addressable Market (TAM) exceeding $500 billion across human and pet nutrition, cosmetics, and pharmaceuticals[11] - Tru Niagen® is identified as a proprietary NAD+ boosting supplement[11] - Approximately 60% of ChromaDex's business is attributed to e-commerce[15] - North America accounts for 75% of Tru Niagen® net sales, followed by APAC with 22%[56] Research and Development - ChromaDex has invested in over $100 million of third-party research supporting the benefits of its proprietary ingredient[11] - ChromaDex holds a strong intellectual property portfolio, including over 80 patents for Niagen® and other NAD+ precursors[11]

Company Overview - ChromaDex is a global authority on NAD+ with a strong intellectual property portfolio for Niagen® and other NAD precursors[8] - The company has strategic partnerships with blue chip companies and a strong financial position, with $4 million LTM Adjusted EBITDA and $28 million in cash as of June 30, 2024[8] - ChromaDex's LTM revenue ended June 2024 was $856 million, with a net loss of $14 million and non-GAAP Adjusted EBITDA of $4 million[25] Consumer Health (Tru Niagen®) - Tru Niagen® has proven to be a proprietary NAD+ boosting supplement with LTM sales of over $80 million[8] - E-commerce represents approximately 60% of the Tru Niagen® business[34] - Annual e-commerce net sales have grown at a CAGR of 85% from 2017 to 2023[35], reaching $512 million in 2023[35] - Gross margin increased from 494% to 608% since the strategic pivot to focus on the consumer product, Tru Niagen®[36] IV & Injectables (Niagen®+) - The company estimates the incumbent NAD+ IV retail market in North America is worth at least $100 million[49] - Niagen®+ IV offers competitive advantages over NAD+ IV, including 75% faster infusion time and minimal side effects[50] Pharmaceutical - ChromaDex is pioneering the development of Parkinson's Disease treatment, with a Phase III study underway involving 400 participants supplemented with NR for 12 months at a 1000mg daily dose, with results expected in 2025[59, 60] Financial Outlook - The company projects net sales growth between 10%-15% year-over-year for 2024[69]

Financial Performance & Guidance - FY25 revenue reached $3.7 billion[10] - FY25 Adjusted EPS was $1.95[45] - FY25 Adjusted EBITDA was $360 million[45] - Q4 FY25 net sales increased by 8.2% and orders increased by 11.1% year-over-year[59] - Q1 FY26 revenue is projected to be between $899 million and $939 million[66] - Q1 FY26 Adjusted Earnings Per Share is guided to be $0.32 to $0.38[66] Cash Flow & Debt - FY25 Cash Flow from Operations was $209 million[47] - FY25 Free Cash Flow was $102 million[48] - Q4 FY25 cash balance was $194 million[52] - Q4 FY25 long-term debt was $1.311 billion[52] - Q4 FY25 Net Debt to EBITDA Ratio was 2.88x[52] Business Segments - North America Contract represented 54% of FY25 revenue[10] - Global Retail accounted for 28% of FY25 revenue[10] - International Contract contributed 18% to FY25 revenue[10]

Equinix Analyst Day 2025 © 2025 Equinix, Inc. 1 Public Disclosure Statement Forward-looking statements This presentation contains references to certain non-GAAP financial measures. For definitions of terms including, but not limited to, "Cash Gross Profit," "Cash Gross Margins," "Cash SG&A," "Adjusted EBITDA," "Funds From Operations," "Adjusted Funds From Operations" and "Adjusted Net Operating Income," and a detailed reconciliation between the non-GAAP financial results presented in this presentation and t ...

Financial Performance - Q4 orders increased by 29% compared to Q3 and 17% year-over-year, indicating a replenishment of backlog[6] - The company more than doubled Q4 operating cash flow year-over-year[6] - Adjusted operating income for FY25 was $49.642 million, compared to a reported operating income of $33.118 million[25] - Inventory efficiency led to a $32 million, or greater than 23%, reduction year-over-year[28] - Share repurchases amounted to $29 million at a volume-weighted average price of $14.23[28] Market Segment Performance - Live Events saw FY orders increase by 31% year-over-year and Q4 orders increase by 44% year-over-year[14] - High School Park & Recreation (HSPR) experienced FY orders growth of 32% year-over-year and Q4 orders growth of 112% year-over-year, achieving record order bookings[15] - International orders decreased by 10% year-over-year for the full year but increased by 14% in Q4[12] - Commercial Transportation orders decreased by 12% year-over-year for the full year and 11% in Q4[10] Strategic Initiatives - The company's business and digital transformation initiatives are in place and on track to drive results[6] - The company incurred $7.085 million in business/digital transformation expenses and $6.825 million in corporate governance expenses for FY25[24] - The company incurred $2 million in "reciprocal" tariffs in the first five weeks of FY26[32]

Financial Performance & Growth Strategy - The company's North American property footprint includes 11 properties with 7,104 slot machines and 142 table games as of December 31, 2023 [11, 14] - The company targets revenue of $635 million in 2024, a 10% increase, and $700 million in 2025 [35] - The company projects Adjusted EBITDAR of $134 million in 2024 and $168 million in 2025 [35] - The company anticipates net cash generation of -$31 million in 2024 and $30 million in 2025 [35] Missouri Casino Operations - In 2023, Cape Girardeau and Caruthersville generated $111.673 thousand in Net Operating Revenue, an 18.4% increase compared to $94.309 thousand in 2019 [50] - In 2023, Cape Girardeau and Caruthersville generated $45.745 thousand in Adjusted EBITDAR, a 45.3% increase compared to $31.475 thousand in 2019 [50] - The Adjusted EBITDAR margin for Cape Girardeau and Caruthersville was 41.0% in 2023, compared to 33.4% in 2019 [50] Strategic Initiatives & Capital Projects - The company is undertaking various capital projects with an estimated total capex requirement of $18 million - $22 million, projected to yield an Adjusted EBITDAR impact of $10 million - $15 million [31] - The Caruthersville land-based casino and hotel project is expected to increase GGR by a projected 22% [101, 102] - The Riverview hotel project is projected to generate $10 million - $12 million in annualized incremental revenue and $3 million - $5 million in annualized incremental Adjusted EBITDAR [82, 83]